Increase of axial and appendicular trabecular and cortical bone density in established osteoporosis with intermittent nasal salmon calcitonin therapy.
The aim of this study was to examine the effect of intranasal administration of salmon calcitonin to a group of 24 postmenopausal women with severe, established osteoporosis (t score < -2.5 SD) and more than one vertebral fracture. The patients were treated with 200 IU of nasal salmon calcitonin daily for 2 months with a subsequent pause of 2 months (3 cycles) and 500 mg calcium daily over a total of 12 months in an open randomized study. The patients were compared with an age matched control group of 18 women of a similar clinical status who were treated with calcium and vitamin D only. In the nasal calcitonin treatment group an increase in the trabecular axial bone density of 2.8% was achieved, as well as increase in trabecular appendicular (forearm) bone density of 1.6%, together with a cortical bone density increase of 1.8% axial and 1% appendicular. Initially, elevated values of urinary deoxypyridinoline were found in 12 women in the nasal calcitonin treatment group; these levels returned to normal under salmon calcitonin nasal therapy and documented the inhibition of increased osteoclastic activity. Cyclic intermittent calcitonin nasal therapy led to a general increase in trabecular and cortical axial and appendicular bone density, marked alleviation of the subjective sensation of pain, and a reduction in the daily dose of accompanying nonsteroidal anti-inflammatory drugs by 50%.
Peichl
P
P
Second Department of Internal Medicine with Rheumatology and Osteology, Kaiser Franz Joseph Hospital, Vienna, Austria.
Rintelen
B
B
Kumpan
W
W
Bröll
H
H
D000281:Administration, Intranasal; D000596:Amino Acids / Q000652:urine; D000700:Analgesics / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D001132:Arm / Q000000981:diagnostic imaging; D015415:Biomarkers / Q000652:urine; D015519:Bone Density / Q000187:drug effects*; D001862:Bone Resorption / Q000517:prevention & control; D002116:Calcitonin / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D002118:Calcium / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007124:Immunoenzyme Techniques; D008875:Middle Aged; D010024:Osteoporosis / Q000150:complications / Q000188:drug therapy*; D010147:Pain Measurement / Q000523:psychology; D010865:Pilot Projects; D012474:Salmon; D016103:Spinal Fractures / Q000517:prevention & control; D013131:Spine / Q000000981:diagnostic imaging; D014057:Tomography, X-Ray Computed; D014807:Vitamin D / Q000627:therapeutic use
D000596:Amino Acids; D000700:Analgesics; D000894:Anti-Inflammatory Agents, Non-Steroidal; D015415:Biomarkers; D014807:Vitamin D; C015484:pyridinoline; C028815:salmon calcitonin; C036020:deoxypyridinoline; D002116:Calcitonin; D002118:Calcium